- Happy Christmas 2020! Peaceful, healthy and happy
- Chengdu Shengnuo Biotechnology Co., Ltd. is a high-tech enterprise with the core technology of peptide synthesis and modification.
- Shengnuo Biotechnology has selected peptide generic drugs with large market capacity and strong market competitiveness at home and abroad for research and development.
- In September 2014, Guojin securities and Shengnuo Biotechnology signed the “counseling agreement”.
Happy Christmas 2020! Peaceful, healthy and happy
Chengdu Shengnuo Biotechnology Co., Ltd. is a high-tech enterprise with the core technology of peptide synthesis and modification.
It has advanced and efficient peptide drug process research and development and large-scale production capacity.
Its main business includes providing pharmaceutical research and customized production services for domestic and foreign pharmaceutical enterprises in the research and development of polypeptide innovative drugs.
Its independent research and development, production and sales are of great significance at home and abroad We have large market capacity and strong competitiveness of polypeptide generic drugs and pharmaceutical products, as well as polypeptide drug production technology transfer services.
In addition, sinobio is also engaged in the processing of levosimendan preparations and the production and export of levosimendan raw materials.
Shengnuo Biotechnology has selected peptide generic drugs with large market capacity and strong market competitiveness at home and abroad for research and development.
It has mastered the large-scale production technology of 15 varieties of API, among which 7 varieties have obtained the production approval in China, 8 varieties have obtained the DMF record (active state) in the United States, and 7 varieties of peptide preparations have obtained 11 production approval in China, The products cover immune system diseases, cancer, cardiovascular, chronic hepatitis B, diabetes, AIDS and obstetric diseases and other peptide drugs play an important role in the field.
In September 2014, Guojin securities and Shengnuo Biotechnology signed the “counseling agreement”.
In April 2018, after friendly negotiation, both sides agreed to terminate the cooperation and terminate the counseling agreement signed by both sides. On September 26, 2018, Shengnuo Biotechnology received the guidance of Minsheng securities. On May 8, 2019, Shengnuo Biotechnology applied to be listed on the sci tech Innovation Board of Shanghai Stock Exchange;
in June 2019, Shengnuo Biotechnology said that according to the development needs of the company, the original application was changed from the original application to be listed on the sci tech Innovation Board of Shanghai Stock Exchange to the venture capital market of Shenzhen Stock Exchange.
On May 27, 2020, Shengnuo Biotechnology will change its listing board from Shenzhen Stock Exchange growth enterprise market to Shanghai Stock Exchange science and technology innovation board.
In this IPO, Shengnuo Biotechnology intends to raise 43328 million yuan, 206.53 million yuan for the 395 kg / a peptide API production line project, 168.42 million yuan for the technical transformation project of preparation industrialization, and 58.33 million yuan for the upgrading project of Engineering Technology Center.